180 related articles for article (PubMed ID: 19571434)
1. Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity.
Katoh M; Yoshioka Y; Nakagawa N; Yokoi T
Drug Metab Pharmacokinet; 2009; 24(3):226-34. PubMed ID: 19571434
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of Kampo medicine on human UGT2B7 activity.
Nakagawa N; Katoh M; Yoshioka Y; Nakajima M; Yokoi T
Drug Metab Pharmacokinet; 2009; 24(6):490-9. PubMed ID: 20045984
[TBL] [Abstract][Full Text] [Related]
3. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin.
Hanioka N; Ozawa S; Jinno H; Ando M; Saito Y; Sawada J
Xenobiotica; 2001 Oct; 31(10):687-99. PubMed ID: 11695848
[TBL] [Abstract][Full Text] [Related]
4. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
Jinno H; Tanaka-Kagawa T; Hanioka N; Saeki M; Ishida S; Nishimura T; Ando M; Saito Y; Ozawa S; Sawada J
Drug Metab Dispos; 2003 Jan; 31(1):108-13. PubMed ID: 12485959
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate.
Yokoi T; Narita M; Nagai E; Hagiwara H; Aburada M; Kamataki T
Jpn J Cancer Res; 1995 Oct; 86(10):985-9. PubMed ID: 7493919
[TBL] [Abstract][Full Text] [Related]
6. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes.
Williams JA; Ring BJ; Cantrell VE; Campanale K; Jones DR; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Nov; 30(11):1266-73. PubMed ID: 12386134
[TBL] [Abstract][Full Text] [Related]
7. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
Gagné JF; Montminy V; Belanger P; Journault K; Gaucher G; Guillemette C
Mol Pharmacol; 2002 Sep; 62(3):608-17. PubMed ID: 12181437
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory Effects of Baicalein Derived from Japanese Traditional Herbal Medicine on SN-38 Glucuronidation.
Satoh T; Igarashi A; Tanno M; Yamada K; Takahashi-Suzuki N; Watanabe K
J Pharm Pharm Sci; 2018; 21(1):195-206. PubMed ID: 29891024
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes.
Hanioka N; Tanabe N; Jinno H; Tanaka-Kagawa T; Nagaoka K; Naito S; Koeda A; Narimatsu S
Life Sci; 2010 Aug; 87(7-8):261-8. PubMed ID: 20620155
[TBL] [Abstract][Full Text] [Related]
10. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1.
Fujita K; Sugiyama M; Akiyama Y; Ando Y; Sasaki Y
Cancer Chemother Pharmacol; 2011 Jan; 67(1):237-41. PubMed ID: 20814789
[TBL] [Abstract][Full Text] [Related]
11. Structure-inhibition relationship of podophyllotoxin (PT) analogues towards UDP-glucuronosyltransferase (UGT) isoforms.
Qi JQ; Cao YF; Sun XY; Hong M; Fang ZZ; Meng DL; Sun DX
Pharmazie; 2015 Apr; 70(4):239-43. PubMed ID: 26012253
[TBL] [Abstract][Full Text] [Related]
12. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
[TBL] [Abstract][Full Text] [Related]
13. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
Saito Y; Sai K; Maekawa K; Kaniwa N; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Sawada J
Drug Metab Dispos; 2009 Feb; 37(2):272-6. PubMed ID: 18981166
[TBL] [Abstract][Full Text] [Related]
14. Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1.
Watanabe Y; Nakajima M; Ohashi N; Kume T; Yokoi T
Drug Metab Dispos; 2003 May; 31(5):589-95. PubMed ID: 12695347
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38.
Iwase M; Fujita KI; Nishimura Y; Seba N; Masuo Y; Ishida H; Kato Y; Kiuchi Y
Cancer Chemother Pharmacol; 2019 May; 83(5):993-998. PubMed ID: 30810774
[TBL] [Abstract][Full Text] [Related]
16. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
Tagawa K; Maruo Y; Mimura Y; Ikushiro S
Toxicol Mech Methods; 2023 Mar; 33(3):197-205. PubMed ID: 35930428
[TBL] [Abstract][Full Text] [Related]
17. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
Girard H; Villeneuve L; Court MH; Fortier LC; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
Drug Metab Dispos; 2006 Jul; 34(7):1220-8. PubMed ID: 16595709
[TBL] [Abstract][Full Text] [Related]
18. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
Yong WP; Ramirez J; Innocenti F; Ratain MJ
Clin Cancer Res; 2005 Sep; 11(18):6699-704. PubMed ID: 16166450
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
Jinno H; Saeki M; Saito Y; Tanaka-Kagawa T; Hanioka N; Sai K; Kaniwa N; Ando M; Shirao K; Minami H; Ohtsu A; Yoshida T; Saijo N; Ozawa S; Sawada J
J Pharmacol Exp Ther; 2003 Aug; 306(2):688-93. PubMed ID: 12730278
[TBL] [Abstract][Full Text] [Related]
20. Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes.
Mano Y; Usui T; Kamimura H
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):211-4. PubMed ID: 17697043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
